Skip to main content
XERS logo

XERS · Xeris Biopharma Holdings, Inc. · Debt

Track XERS — free
$10.13 +1.05 (+11.56%) At close · Oct 5
Market Cap
$1.66B
Shares
182.32M
Volume · Oct 5 4.66M Avg daily vol (3M) 2.2M

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-06-30 USD 252,590,000 10-Q filed 2026-08-06
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 63,783,000
Noncurrent debt carrying amount
USD 188,807,000
Operating lease liabilities 2026-06-30 USD 36,852,000 10-Q filed 2026-08-06
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 6,310,000
Noncurrent operating lease liabilities
USD 30,542,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1867096 CUSIP 98422E103 13F (30d) 5 filings 5 filers Visit website Investor relations